Kyverna Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 42/100
What the filing says
Kyverna hired Nadia Dac as Chief Commercial Officer, effective May 4, 2026, with $520,000 base salary, 40% target bonus, $275,000 sign-on bonus, and 300,000 stock options. Separately, the company amended its $25M outstanding Term A loan (from Oxford Finance and affiliates, dated October 2025) on July 8, 2026, adding non-utilization fees (1% if undrawn by Dec 31, 2026; 1% for Term B if undrawn by Sept 30, 2027), contingent access to $20M Term C loans (two phases, tied to KYV-101 sales milestones and clinical trial data), and a $187,500 amendment fee.
Why this rating
CCO hire is routine leadership addition. Loan amendment extends runway but adds conditions tied to product sales and clinical data—material contingency risk relative to $64.5M market cap, but no immediate cash outflow beyond $187.5K fee.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.